XTalks

NOVEMBER 20, 2023

AstraZeneca has won its first-in-class approval for its AKT inhibitor Truqap (capivasertib) in combination with Faslodex (fulvestrant) for treating patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer. It was also given FDA priority review.

HR 98

HR FDA Approval Gene Trials 98

XTalks

MAY 20, 2022

The injection is intended to regulate blood sugar, in conjunction with diet and exercise, in adults with type 2 diabetes. Life science industry data analytics company Evaluate Vantage predicts that Mounjaro could bring in $4.9 Related: Tirzepatide Obesity Drug Shown to Reduce Body Weight by 20 Percent in Eli Lilly Trial.

Insulin 52

Insulin Life Science Drugs Sales 52

XTalks

APRIL 29, 2022

Eli Lilly announced that its obesity drug tirzepatide has scored favorably in a late-stage clinical trial, with results showing that people who took the drug lost an average of 50 pounds, or 21 percent, of their body weight compared to placebo. percent and 22.5 percent, respectively, compared to placebo.

Trials 98

Trials Drugs FDA Approval Clinical Trials 98

The Pharma Data

APRIL 11, 2023

Bayer will present the first clinical Phase 1 results on aryl hydrocarbon receptor (AhR) inhibitor BAY 2416964, the company’s most advanced Immuno-Oncology program.

Research 40

Research Clinical Trials Clinical Trials Trials 40

XTalks

JULY 2, 2021

Currently, there is no scientific evidence to suggest that the vaccines induce any hormonal changes that would lead to irregular periods. This is because the processes that maintain the uterine lining, including the placenta, during pregnancy are different than those that regulate the normal menstrual cycle.

Vaccination 105

Vaccination Vaccine Protein Immune Response 105

XTalks

SEPTEMBER 17, 2020

In rare disease trials, it’s not always feasible to choose clinically-relevant endpoints to measure the efficacy of a new therapeutic. Symptoms and Etiology: Caused by an overproduction of growth hormone, acromegaly primarily affects adults. Acromegaly. Prevalence: 50 to 70 people per 1 million.

Trials 98

Trials Gene Hormones Clinical Trials 98

XTalks

FEBRUARY 5, 2024

In the dynamic landscape of oncology therapeutics, understanding the trends and performances of leading drugs is crucial for stakeholders across the healthcare and life sciences sectors. The benefits of Verzenio are supported by promising clinical data. Internationally, revenue reached $355.7

FDA Approval 101

FDA Approval Drugs Sales Development 101

XTalks

AUGUST 2, 2023

5) Ibrance (palbociclib) Ibrance is a chemotherapy drug indicated for hormone receptor positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer. It is a CDK 4/6 inhibitor that is taken in combination with other hormonal therapies to stop the growth of cancer and healthy cells. billion in 2022.

Sales 98

Sales Manufacturing FDA Approval Life Science 98

XTalks

FEBRUARY 8, 2024

Diabetes remains a critical global challenge, affecting millions of lives and commanding significant attention from the medical, life sciences and pharmaceutical sectors. The efficacy and safety of Rybelsus in reducing blood sugar in patients with type 2 diabetes were investigated in various clinical trials.

Sales 52

Sales Insulin FDA Approval Drugs 52

XTalks

FEBRUARY 5, 2024

In the dynamic landscape of oncology therapeutics, understanding the trends and performances of leading drugs is crucial for stakeholders across the healthcare and life sciences sectors. The benefits of Verzenio are supported by promising clinical data. Internationally, revenue reached $355.7

FDA Approval 52

FDA Approval Drugs Sales Development 52

XTalks

MARCH 1, 2021

And while conventional dry eye can have a number of causes — including blepharitis, hormone-related changes in post-menopausal women and contact lens use — mask-associated dry eye is largely cropping up in people who wear face masks for extended periods during the day.

Sales 119

Sales Drugs Life Science Containment 119

Drug Discovery World

MAY 9, 2024

RA: Tell us how OXE103 works? MW: OXE103 (ghrelin) is a 28 amino acid neuro-peptide hormone that crosses the blood brain barrier and is responsible for maintaining brain energy homeostasis and neuroprotection related to neuronal cell preservation, axonal connectivity and decreased inflammation. Rest Is not Enough!

Development 72

Development Hormones Drugs Trials 72

pharmaphorum

MARCH 5, 2021

For International Women’s Day, Medidata’s global compliance and strategy lead Fiona Maini discusses the importance of increasing female participation in clinical trials and how technology may solve some of the barriers. Levelling the field through technology.

Clinical Trials 116

Clinical Trials Clinical Trials Trials Vaccination 116

Pharmaceutical Technology

JANUARY 22, 2023

The mutation leads to disordered thyroid hormone transport, which causes patients to experience intellectual and motor disabilities. Egetis is banking on tiratricol, an oral small molecule that restores dysfunctional thyroid hormone signalling, to be the first drug approved for this condition. In clinical trials, the drug showed a 3.8-point

Drugs 317

Drugs Gene Hormones Clinical Trials 317